Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Anahita Anderson

Nurse Practitioner, Family Jackson, TN Nurse Practitioner

NPI 1306389903 CMS profile 10890324

27A Medical Center Dr, Jackson, TN 38301

Open in the dashboard

General payments

$85,247

735 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anahita Anderson of Jackson, TN is reported in the CMS Open Payments database as having received $85,247 across 735 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $32,882 193
2024 General $23,527 184
2023 General $19,605 113
2022 General $6,681 129
2021 General $2,551 116

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anahita Anderson
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Anahita Anderson were reported at $32,882. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Anahita Anderson Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,551 $124 $35–$379 $132
2022 $6,681 $141 $44–$430 $149
2023 $19,605 $154 $49–$476 $160
2024 $23,527 $165 $51–$504 $164
2025 $32,882 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $65,326 271 payments
  2. Ironwood Pharmaceuticals, Inc $7,621 25 payments
  3. Enterra Medical, Inc. $2,188 8 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,731 118 payments
  5. Janssen Biotech, Inc. $1,240 55 payments
  6. Ardelyx, Inc. $821 34 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $690 31 payments
  8. Nestle HealthCare Nutrition Inc. $640 34 payments
  9. Madrigal Pharmaceuticals $619 11 payments
  10. Gilead Sciences, Inc. $387 14 payments
  11. Other $3,983 134 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $58,300 34 payments
  2. Food and Beverage $17,104 665 payments
  3. Travel and Lodging $9,646 34 payments
  4. Consulting Fee $175 1 payment
  5. Education $21 1 payment
Products named General payments · program years 2021–2025
  1. LINZESS Gastroenterology $43,662 123 payments
  2. CREON $16,394 85 payments
  3. Linzess Gi $7,621 25 payments
  4. RINVOQ $1,730 68 payments
  5. XIFAXAN $1,372 89 payments
  6. SKYRIZI $1,236 40 payments
  7. STELARA $1,000 35 payments
  8. IBSRELA $821 34 payments
  9. ZENPEP $769 41 payments
  10. TREMFYA $735 24 payments
  11. Other $7,676 299 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 46 drugs

Part D claims

5,486

Median for Nurse Practitioner: 389

Drug cost

$1,472,347

Median for Nurse Practitioner: $21,885

Branded share of claims

27.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 712 $625,645
Stelara Ustekinumab Brand 12 $269,262
Zenpep Lipase/Protease/Amylase Brand 31 $131,427
Xifaxan Rifaximin Brand 39 $122,101
Creon Lipase/Protease/Amylase Brand 49 $96,465
Movantik Naloxegol Oxalate Brand 64 $40,487
Trulance Plecanatide Brand 35 $30,423
Famotidine Generic 1,187 $27,838
Viberzi Eluxadoline Brand 19 $25,199
Dexlansoprazole Dr Dexlansoprazole Brand 77 $16,030

The 10 drugs with the highest cost, of 46 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$57,630

Medicare's payments for the services billed

Medicare patients

515

Average age 72

Services billed

1,512

305 women, 210 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 38%
Ischemic heart disease 37%
Chronic kidney disease 29%
Depression 26%
COPD 21%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LINZESS
$14,746 712 —
CREON
$5,155 49 —
SKYRIZI
$350 — —
OMVOH
$293 — —
IBSRELA
$262 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

735 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record